CBX (Fig. 1c), a water-soluble disodium salt of glycyrrhetinic acid hemisuccinate, which is clinically used for the treatment of peptic, esophageal, and oral ulceration [29], showed the most potent effect on FOXO3 inhibition in our screening (Supplementary Fig. S2) and was therefore selected for further studies to investigate its efficacy to inhibit the transcriptional activity of FOXO3 and its potential therapeutic use in NB treatment. The gene discussed is CBX1; the disease is neuroblastoma.